期刊文献+

前列腺癌患者睾酮替代治疗的安全性研究进展

Research progress on the safety of testosterone replacement therapy in patients with prostate cancer
下载PDF
导出
摘要 男性性腺功能减退症是由于雄激素缺乏引起的一种临床综合征,睾酮替代治疗(TRT)是其首选治疗方法.但对于既往有前列腺癌病史的患者,TRT的应用一直存在争议.近年来,文献报道了不同阶段前列腺癌患者接受TRT的安全性研究,包括癌前病变期,主动监测、根治性治疗后及进展期前列腺癌.本文回顾这些文献并对TRT在前列腺癌患者中应用的安全性研究进展进行综述. Hypogonadism in men is a clinical syndrome caused by androgen deficiency,for whom testosterone replacement therapy(TRT)is the preferred treatment.However,the use of TRT has been controversial in patients with a previous history of prostate cancer.In recent years,studies on the safety of TRT in patients with prostate cancer at different stages have been reported,including pre-cancerous stage,active surveillance,post-radical treatment and advanced prostate cancer.This article reviews the literatures and the progress in the application safety of TRT in patients with prostate cancer.
作者 汪奇波 朱绍兴 WANG Qi-bo;ZHU Shao-xing(Department of Urology,Cancer Hospital of the University of Chinese Academy of Sciences,Zhejiang Province,Hangzhou310022,China)
出处 《中国当代医药》 2020年第8期16-18,共3页 China Modern Medicine
基金 浙江省自然科学基金资助项目(LY16H160034)。
关键词 前列腺癌 性腺功能减退症 睾酮 替代治疗 Prostate cancer Hypogonadism Testosterone Replacement therapy
  • 相关文献

参考文献2

二级参考文献69

  • 1[13]Goldray D, Weisman Y, Jaccard N et al. Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH)[J]. J Clin Endocrinol Metab, 1993, 76:288~290.
  • 2[14]Behre HM, Kliesch S, Leifke E et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men [J]. J Clin Endocrinol Metab, 1997, 82:2386~2390.
  • 3[15]Leifke E, Korner HC, Link TM et al. Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area, and paraspinal muscle area in hypogonadal men [J]. Eur J Endocrinol, 1998, 138:51~58.
  • 4[16]Katznelson L, Finkelstein JS, Schoenfeld DA et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism [J]. J Clin Endocrinol Metab, 1996,81:4358~4365.
  • 5[17]Reid IR, Wattie DJ, Evans MC et al. Testosterone therapy in gluco-corticoid treated men [J]. Arch Intern Med, 1996, 156:1173~1177.
  • 6[18]Snyder PJ, Peachey H, Hannoush P et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age [J]. J Clin Endocrinol Metab, 1999,84:1966~1972.
  • 7[19]Bhasin S, Storer TW, Berman N et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men [J]. J Clin Endocrinol Metab, 1997,82:407~413.
  • 8[20]Bhasin S, Storer TW, Berman N et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men [J]. N Engl J Med, 1996, 335:1~7.
  • 9[21]Tenover JS. Effects of testosterone supplementation in the aging male [J]. J Clin Endocrinol Metab, 1992,75:1092~1098.
  • 10[22]Morley JE, Perry HM, Kaiser FE et al. Effects of testosterone replacement therapy in hypogonadal males: a preliminary study [J]. J Am Geriatr Soc, 1993,41:149~152.

共引文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部